Company Filing History:
Years Active: 2012
Title: Innovations by Inventor Maria Léonor Nogueira
Introduction
Maria Léonor Nogueira is an accomplished inventor based in Toulouse, France. He has made significant contributions to the field of medical diagnostics, particularly in the detection of rheumatoid arthritis. With one patented invention to his name, Nogueira has advanced the understanding of autoimmune conditions through innovative methodologies.
Latest Patents
Nogueira holds a patent for a groundbreaking method titled "Method for detecting rheumatoid arthritis-specific autoantibodies." This innovative process involves detecting anti-filaggrin autoantibodies associated specifically with rheumatoid arthritis in biological samples. Nogueira’s method utilizes a filaggrin molecule, free of citrulline residues, along with its respective peptides to interact with biological samples. The resulting immune complexes are quantified, determining the presence of relevant autoantibodies based upon value thresholds.
Career Highlights
Currently, Maria Léonor Nogueira is associated with bioMérieux, Inc., a global leader in in vitro diagnostics. His work within the company focuses on enhancing diagnostic methods to improve patient outcomes, particularly for those with autoimmune diseases such as rheumatoid arthritis. Nogueira’s effort in patenting his method has added valuable intellectual property to bioMérieux's extensive portfolio of medical innovations.
Collaborations
During his career, Nogueira has collaborated with notable peers, including Brigitte Incaurgarat and Michel C Jolivet. These professional relationships have enriched his research, enabling the fusion of different expertise and fostering a collaborative spirit in the pursuit of medical advancements.
Conclusion
Maria Léonor Nogueira's innovative work stands as a testament to the power of invention in the medical field. His patented methods provide a new avenue for the detection of rheumatoid arthritis-specific autoantibodies, reflecting his commitment to improving diagnostic capabilities. As Nogueira continues to work with bioMérieux, Inc., his contributions may pave the way for future breakthroughs in the understanding and treatment of autoimmune diseases.